Cytokinetics Posts $1.50 Q2 Loss Per Share, Wider Than Expected
CYTK has more than doubled off its 52-week low of $32.89.
Summary
Cytokinetics reported a Q2 loss of $1.50 per share, a significant miss versus the consensus estimate of a narrower loss. The company is in the early stages of its commercial launch of MYQORZO (aficamten) for obstructive HCM, following UK authorization and NICE recommendation in late July, and reported MYQORZO net product revenue of $25 million. The wider loss likely reflects higher spending to support the launch and ongoing clinical programs. Cytokinetics also expects to submit a supplemental NDA for aficamten in non-obstructive HCM in the fourth quarter. With a market cap around $10 billion, the magnitude of the miss could pressure the stock as investors reassess the path to profitability. The next catalyst is the Q2 earnings call, where management will provide revenue guidance and launch metrics.
At the time of this announcement, CYTK was trading at $81.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.2B. The 52-week trading range was $32.89 to $88.31. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.